Search - tctmd.com

Displaying 581 - 600 of 692

Sort: Relevancy | Date

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Darshan Doshi

October 11, 2015

Presentation TCT 2015

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

Presenter: Samir R. Kapadia, Jeffrey J. Popma

October 11, 2015

Presentation TCT 2015

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Roxana Mehran

October 11, 2015

Presentation TCT 2015

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Shamir R. Mehta

October 11, 2015

Presentation TCT 2015

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Patrick W. Serruys

October 11, 2015

Presentation TCT 2015

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Presenter: Ori Ben-Yehuda, Ajay J. Kirtane, Sripal Bangalore

October 11, 2015

Presentation TCT 2015

Considerations and Recommendations for Future Clinical Trials in Device-Based Hypertension Treatments

Presenter: Farrell O. Mendelsohn, William B. White

October 11, 2015

Presentation TCT 2015

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Presenter: Stuart J. Pocock, Jan Tijssen, David J. Cohen

October 11, 2015

Presentation TCT 2015

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Presenter: Stuart J. Pocock, Jan Tijssen, John L. Petersen

October 11, 2015

Presentation TVT 2015

Insights From the US TVT Registry

Presenter: John D. Carroll

June 05, 2015

Presentation TVT 2015

NOTION in All-Comers

Presenter: Lars Sondergaard

June 05, 2015

Presentation TVT 2015

CoreValve US 2-Year Follow-up

Presenter: Michael J. Reardon

June 05, 2015

Presentation TVT 2015

PARTNER 5-Year Follow-up

Presenter: Martin B. Leon

June 05, 2015

Presentation TVT 2015

Bicuspid Aortic Valve Disease

Presenter: Mathew Williams

June 05, 2015

Presentation TVT 2015

GARY

Presenter: Helge Möllmann

June 05, 2015

Presentation TVT 2015

FRANCE 2

Presenter: Helene Eltchaninoff

June 05, 2015

Presentation TVT 2015

UK Registry

Presenter: Neil E. Moat

June 05, 2015

Advertisement

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

From SYMPLICITY HTN-3 to Ongoing Renal Denervation Studies: What Answers Can We Expect (and Not Expect) From the Ongoing RDN Studies?

Updates From the PARTNER Trials 2: Reports From Selected Substudies

Updates From the PARTNER Trials 1: Follow-up From the Inoperable and High-Risk Subgroups

From WOEST, DAPT, and PEGASUS to GLOBAL LEADERS and TWILIGHT: What Answers Can We Expect (and Not Expect) From GLOBAL LEADERS and TWILIGHT?

From PRAMI, CvLPRIT, and Other Studies to COMPLETE: What Answers Can We Expect (and Not Expect) From COMPLETE?

From SYNTAX to EXCEL: What Answers Can We Expect (and Not Expect) From EXCEL?

From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA?

Considerations and Recommendations for Future Clinical Trials in Device-Based Hypertension Treatments

Strategy Trials vs Device/Drug Comparisons: Important Considerations

Observational vs Randomized Trials: Strengths and Weaknesses (With Case Examples)

Insights From the US TVT Registry

NOTION in All-Comers

CoreValve US 2-Year Follow-up

PARTNER 5-Year Follow-up

Bicuspid Aortic Valve Disease

GARY

FRANCE 2

UK Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content